Some clinical factors affecting quality of the response to ustekinumab for psoriasis

Journal of Dermatology

Volumn 41, Issue 8, 2014, Pages 690-696

  Umezawa, Yoshinori ^a   Saeki, Hidehisa ^a   Nakagawa, Hidemi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

biologics; body mass index; psoriasis; severity; ustekinumab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; INFLIXIMAB; RETINOID; USTEKINUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; SEX RATIO; SMOKING HABIT; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; ADVERSE EFFECTS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; BODY MASS INDEX; BODY WEIGHT; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905702796     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12538     Document Type: Article

References (21)

1. Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study G. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-252.
2. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ,. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-691.
3. Naldi L, Chatenoud L, Linder D, et al,. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
4. Herron MD, Hinckley M, Hoffman MS, et al,. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
5. Schon MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
6. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB,. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67: 768-773.
7. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H,. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009; 54: 61-63.
8. Lebwohl M, Yeilding N, Szapary P, et al,. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-579.
9. Naldi L, Addis A, Chimenti S, et al,. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-373.
10. Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G,. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat 2012; 23: 404-409.
11. Gerdes S, Zahl VA, Weichenthal M, Mrowietz U,. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010; 220: 38-43.
12. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingard E, Stahle M,. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
13. Huerta C, Rivero E, Rodriguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-1565.
14. Fortes C, Mastroeni S, Leffondre K, et al,. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141: 1580-1584.
15. Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV,. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011; 165: 1162-1168.
16. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics R. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006; 45: 1558-1565.
17. Soderlin MK, Petersson IF, Geborek P,. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012; 41: 1-9.
18. Di Lernia V, Ricci C, Lallas A, Ficarelli E,. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat 2014; 25: 73-74.
19. Ruiz Salas V, Puig L, Alomar A,. Ustekinumab in clinical practice: response depends on dose and previous treatment. J Eur Acad Dermatol Venereol 2012; 26: 508-513.
20. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R,. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-1040.
21. Woolf RT, Smith CH,. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010; 6: 957-966.